{"id":396840,"date":"2020-12-09T16:33:29","date_gmt":"2020-12-09T21:33:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396840"},"modified":"2020-12-09T16:33:29","modified_gmt":"2020-12-09T21:33:29","slug":"biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/","title":{"rendered":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer<\/b><\/p>\n<p class=\"bwalignc\"><i>&#8211; Specific targetable bacteria observed in over 80 percent of patient colorectal tumor samples &#8211; <\/i><\/p>\n<p class=\"bwalignc\"><i>&#8211; Results featured at<\/i><i>the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 &#8211;<\/i><\/p>\n<p>NESS ZIONA, Israel&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, <i>Fusobacterium nucleatum,<\/i> in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications. The analysis confirmed the presence of <i>Fusobacterium nucleatum <\/i>in over 80 percent of tumor samples obtained from patients with colorectal cancer and identified <i>Fusobacterium nucleatum animalis <\/i>as the most prevalent subspecie.\n<\/p>\n<p>\nIn addition, the Company reported successful engineering of a functional fluorescence gene payload into<i> Fusobacterium nucleatum<\/i> phage and disclosed three candidate payloads which are being evaluated for delivery to the tumor microenvironment via phage. Candidate payloads include gene-encoding immune-stimulating proteins GM-CSF and IL-15 as well as the pro-drug converting enzyme cytosine deaminase. The BiomX colorectal cancer program utilizes phage therapy in combination with checkpoint inhibitors in order to target bacteria that are naturally present within tumors, with the aim of converting \u2018cold\u2019 tumors to \u2018hot\u2019 by delivering a payload to the tumor.\n<\/p>\n<p>\nThe results are featured in a poster presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 and will be available at the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.biomx.com%2Fpublications-2%2F&amp;esheet=52345708&amp;newsitemid=20201209005890&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.biomx.com%2Fpublications-2%2F&amp;index=1&amp;md5=15a54fa20fe2cbbd054b1589ca423642\">https:\/\/www.biomx.com\/publications-2\/<\/a>.<b \/>Presentation details are as follows:\n<\/p>\n<p><b>Title:<\/b> Novel Analysis of <i>Fusobacterium Nucleatum<\/i> Subspecies in Human Colorectal Cancer and Engineering of Therapeutic Bacteriophage<br \/>\n<br \/><b>Lead Author:<\/b> Lihi Ninio-Many, Ph.D., Project Leader, BiomX\n<\/p>\n<p><b>About BiomX<\/b><\/p>\n<p>\nBiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.\n<\/p>\n<p>\nAdditional information is available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.biomx.com&amp;esheet=52345708&amp;newsitemid=20201209005890&amp;lan=en-US&amp;anchor=www.biomx.com&amp;index=2&amp;md5=dc5d8c2f7a61e170678279a330a70208\">www.biomx.com<\/a>.\n<\/p>\n<p><b>Safe Harbor Language <\/b><\/p>\n<p>\nThis press release contains express or implied \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when this press release discusses the potential engineering of phage for the delivery of genetic payloads for therapeutic applications, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management\u2019s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, invest should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption \u201cRisk Factors\u201d in BiomX\u2019s first Current Report on Form 8-K filed on December 4, 2020 and additional disclosures BiomX makes in its filings with the Securities and Exchange Commission (the \u201cSEC\u201d), which are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52345708&amp;newsitemid=20201209005890&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=d5d7a478540c5376515cf679e0c908da\">www.sec.gov<\/a>. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201209005890\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201209005890\/en\/<\/a><\/span><\/p>\n<p>\nNoel Kurdi, BiomX<br \/>\n<br \/>VP Investor Relations and Strategy<br \/>\n<br \/>(646) 241-4400<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:noelk@biomx.com\">noelk@biomx.com <\/a><\/p>\n<p>\nMedia contact:<br \/>\n<br \/>Rich Allan, Solebury Trout<br \/>\n<br \/>(646) 378-2958<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:rallan@soleburytrout.com\">rallan@soleburytrout.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Israel Middle East<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Oncology Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer &#8211; Specific targetable bacteria observed in over 80 percent of patient colorectal tumor samples &#8211; &#8211; Results featured atthe European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 &#8211; NESS ZIONA, Israel&#8211;(BUSINESS WIRE)&#8211; BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, Fusobacterium nucleatum, in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications. The analysis confirmed the presence of Fusobacterium nucleatum in over 80 percent of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396840","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer &#8211; Specific targetable bacteria observed in over 80 percent of patient colorectal tumor samples &#8211; &#8211; Results featured atthe European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 &#8211; NESS ZIONA, Israel&#8211;(BUSINESS WIRE)&#8211; BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, Fusobacterium nucleatum, in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications. The analysis confirmed the presence of Fusobacterium nucleatum in over 80 percent of &hellip; Continue reading &quot;BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T21:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer\",\"datePublished\":\"2020-12-09T21:33:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/\",\"name\":\"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-09T21:33:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk","og_description":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer &#8211; Specific targetable bacteria observed in over 80 percent of patient colorectal tumor samples &#8211; &#8211; Results featured atthe European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 &#8211; NESS ZIONA, Israel&#8211;(BUSINESS WIRE)&#8211; BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, Fusobacterium nucleatum, in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications. The analysis confirmed the presence of Fusobacterium nucleatum in over 80 percent of &hellip; Continue reading \"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T21:33:29+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer","datePublished":"2020-12-09T21:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/","name":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-09T21:33:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201209005890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-announces-preclinical-results-of-analysis-of-patient-samples-and-engineering-of-phage-for-therapeutic-applications-in-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396840"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}